ClinicalTrials.gg
CompletedNCT00061815Updated Apr 12, 2010

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

A Phase 3 interventional study of cetuximab and oxaliplatin in Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
62nd of 185
102 · median 60
Started
2003
with 5 others
Phase 3
29 of 187
5 open now
Registered
7th of 187
by date
Lead sponsor
7 of 187
Eli Lilly and Company

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 62nd largest by enrollment of the 185 interventional ones that give a count, is one of 6 that started in 2003, is one of 29 in phase 3, and was the 7th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented colorectal cancer which is EGFR-positive and is .
  • Prior irinotecan, alone or in combination, as treatment of metastatic disease.

Exclusion criteria

Exclusion Criteria:

  • A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy.
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Known in the central nervous system.
  • Symptomatic sensory or peripheral neuropathy.
  • More than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer.
  • Prior oxaliplatin therapy.
  • Prior cetuximab or other therapy which targets the EGF pathway.
  • Prior chimerized or murine monoclonal antibody therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Cetuximab+FOLFOX4

    * Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion * Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion * Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes

    Biological: cetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: 5-fluorouracil

  • Active comparator
    FOLFOX4.

    * Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion. * Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion.

    Drug: oxaliplatin · Drug: leucovorin · Drug: 5-fluorouracil

Interventions

06

What researchers measure

Primary outcomes

  1. Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.

    Time frame: Every six weeks

Secondary outcomes

  1. Compare the response rates between the two treatment arms.

    Time frame: Every six weeks

  2. Compare progression-free survival between the two treatment arms.

    Time frame: Every six weeks

  3. Duration of response within each treatment arm.

    Time frame: Every six weeks

  4. Time to response within each treatment arm.

    Time frame: Every six weeks

  5. Compare the safety profiles between the two treatment arms.

    Time frame: Every six weeks

  6. Compare the quality of life (QOL)between the two treatment arms.

    Time frame: Every six weeks

  7. Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.

    Time frame: Every six weeks

07

Study locations

39 sites
  • ImClone Investigational Site
    Little Rock, Arkansas 72205, United States
  • ImClone Investigational Site
    Springdale, Arkansas 72764, United States
  • ImClone Investigational Site
    Fountain Valley, California 92708, United States
  • ImClone Investigational Site
    Gilroy, California 95020, United States
  • ImClone Investigational Site
    Greenbrae, California 94904, United States
  • ImClone Investigational Site
    Orange, California 92868, United States
  • ImClone Investigational Site
    Pomona, California 91767, United States
  • ImClone Investigational Site
    San Diego, California 92120, United States
  • ImClone Investigational Site
    Vista, California 92083, United States
  • ImClone Investigational Site
    Hartford, Connecticut 06105, United States
  • ImClone Investigational Site
    Norwalk, Connecticut 06856, United States
  • ImClone Investigational Site
    Stamford, Connecticut 06902, United States
  • ImClone Investigational Site
    Waterbury, Connecticut 06708, United States
  • ImClone Investigational Site
    Boynton Beach, Florida 33435, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32207, United States
  • ImClone Investigational Site
    Leesburg, Florida 34748, United States
  • ImClone Investigational Site
    Orlando, Florida 32804, United States
  • ImClone Investigational Site
    Tampa, Florida 33613, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30309, United States
  • ImClone Investigational Site
    Macon, Georgia 31201, United States
  • ImClone Investigational Site
    Louisville, Kentucky 40202, United States
  • ImClone Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • ImClone Investigational Site
    Baltimore, Maryland 21225, United States
  • ImClone Investigational Site
    Clinton, Maryland 20735, United States
  • ImClone Investigational Site
    St. Joseph, Michigan 49085, United States
  • ImClone Investigational Site
    Kansas City, Missouri 64131, United States
  • ImClone Investigational Site
    Rolla, Missouri 65401, United States
  • ImClone Investigational Site
    Hackensack, New Jersey 07601, United States
  • ImClone Investigational Site
    Armonk, New York 10504, United States
  • ImClone Investigational Site
    Brooklyn, New York 11235, United States
  • ImClone Investigational Site
    East Setauket, New York 11733, United States
  • ImClone Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • ImClone Investigational Site
    Bismarck, North Dakota 58501, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • ImClone Investigational Site
    Charleston, South Carolina 29406, United States
  • ImClone Investigational Site
    Knoxville, Tennessee 37920, United States
  • ImClone Investigational Site
    Nashville, Tennessee 37203, United States
  • ImClone Investigational Site
    Ogden, Utah 84403, United States
  • ImClone Investigational Site
    Richmond, Virginia 23230, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Dec 2004 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2003
First posted
Jun 6, 2003
Start
Mar 2003
Primary completionActual
Dec 2004
CompletionActual
Nov 2005
Last update
Apr 12, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00061815
First posted
Jun 6, 2003
Start date
Mar 2003
Primary completion
Dec 2004
Completion
Nov 2005
Last update
Apr 12, 2010

Study contacts

E-mail: ClinicalTrials@ ImClone.com
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion